Compare · MMM vs NVNO
MMM vs NVNO
Side-by-side comparison of 3M Company (MMM) and enVVeno Medical Corporation (NVNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and NVNO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $85.26B, about 15484.3x NVNO ($5.5M).
- MMM has been more active in the news (12 items in the past 4 weeks vs 1 for NVNO).
- MMM has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- 3M Company
- enVVeno Medical Corporation
- Price
- -
- -
- Market cap
- $85.26B
- $5.5M
- 1M return
- -0.03%
- -
- 1Y return
- +7.81%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 1
- Recent ratings
- 25
- 0
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Latest MMM
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- 13-Year-old Raji Doshi named America's Top Young Scientist for inventing an algae-aragonite alkalinity system to reduce CO2-driven ocean acidification
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 3 filed by 3M Company
- 3M Announces Upcoming Investor Event
- EVP & Chief Financial Officer Maheshwari Anurag exercised 10,944 shares at a strike of $163.02 and covered exercise/tax liability with 4,991 shares, increasing direct ownership by 93% to 12,365 units (SEC Form 4)
- Wells Fargo initiated coverage on 3M with a new price target
- 3M upgraded by Bernstein with a new price target
Latest NVNO
- enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
- enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
- Director Duhay Francis sold $123 worth of shares (11 units at $11.21) as part of a pre-agreed trading plan, decreasing direct ownership by 0.47% to 2,351 units (SEC Form 4)
- enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
- enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
- JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
- SEC Form S-3 filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve